Lantern Pharma Balance Sheet Health
Financial Health criteria checks 6/6
Lantern Pharma has a total shareholder equity of $30.9M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $35.6M and $4.7M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$33.26m |
| Equity | US$30.93m |
| Total liabilities | US$4.66m |
| Total assets | US$35.59m |
Recent financial health updates
Lantern Pharma (NASDAQ:LTRN) Is In A Good Position To Deliver On Growth Plans
Jun 12
We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely
Feb 28We're Not Very Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Rate
Nov 06Lantern Pharma (NASDAQ:LTRN) Is In A Good Position To Deliver On Growth Plans
Jul 20We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely
Apr 04Here's Why We're Not Too Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation
Dec 19Recent updates
Lantern Pharma (NASDAQ:LTRN) Is In A Good Position To Deliver On Growth Plans
Jun 12We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely
Feb 28We're Not Very Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Rate
Nov 06Lantern Pharma (NASDAQ:LTRN) Is In A Good Position To Deliver On Growth Plans
Jul 20We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely
Apr 04Here's Why We're Not Too Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation
Dec 19We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely
Sep 02Lantern Pharma gets FDA nod to start mid-stage study of LP-300 in lung cancer
Jul 14Companies Like Lantern Pharma (NASDAQ:LTRN) Are In A Position To Invest In Growth
May 20Here's Why We're Not Too Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation
Feb 02We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely
Oct 13Lantern Pharma: Consider A Speculative Long-Term Investment In This AI Drug Discoverer
Aug 24Lantern Pharma: Drug Recycling With AI
Jun 08We're Not Very Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Rate
May 05Lantern Pharma reports Q1 results
May 03Here's What Lantern Pharma Inc.'s (NASDAQ:LTRN) Shareholder Ownership Structure Looks Like
Feb 19
Lantern Pharma announces antibody drug conjugate tie-up with Califia Pharma
Jan 04Who Has Been Buying Lantern Pharma Inc. (NASDAQ:LTRN) Shares?
Dec 28Lantern: Early Stage 'Smart Drug' Discovery Company
Nov 25Financial Position Analysis
Short Term Liabilities: LTRN's short term assets ($35.3M) exceed its short term liabilities ($4.6M).
Long Term Liabilities: LTRN's short term assets ($35.3M) exceed its long term liabilities ($54.7K).
Debt to Equity History and Analysis
Debt Level: LTRN is debt free.
Reducing Debt: LTRN had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: LTRN has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: LTRN has sufficient cash runway for 2.1 years if free cash flow continues to reduce at historical rates of 31.2% each year.